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Introduction
Hematopoietic cells are important targets for somatic gene therapy, considering their availability for in vitro manipulation and their enormous functional capacity. In selected diseases, hematopoietic gene therapy has clearly shown clinical efficacy, creating new perspectives for the entire field. [1] [2] [3] [4] Due to the high proliferative potential of hematopoietic cells, stable introduction of transgenes into cellular chromosomes is required for successful genetic modification. Retroviral (including lentiviral) vectors confer a predictable efficiency of stable transgene insertion with a controlled copy number. 5, 6 However, secondary leukemias have been reported in which insertional activation of cellular proto-oncogenes by inserted retroviral vectors represented the initiating event, both in animal models [7] [8] [9] and in a clinical trial. 10 To overcome the present uncertainty in the scientific and regulatory community, systematic research needs to be conducted to address the frequency of insertional mutagenesis, the role of contributing factors, and the impact of vector design. 6 Indeed, all cases of leukemogenic complications observed to date in clinical trials or animal models of gene therapy involved the use of conventional retroviral vectors with long terminal repeats (LTRs) containing strong enhancer-promoters. This configuration is derived from their strongly leukemogenic parental viruses and may trigger both distant enhancer interactions and activation of 3' located genes by promoter insertion. 11 Self-inactivating (SIN) retroviral vectors which contain only one internal enhancer-promoter should reduce the incidence of interactions with nearby cellular genes. 6 Experimental evidence supporting this hypothesis would have important implications for the design of future clinical trials.
Considering random vector insertion and a hypothetical "vulnerable region" of 10 kb that might lead to upregulation of a neighboring proto-oncogene following retroviral vector insertion, the risk of activating insertions in a given proto-oncogene per treated cell might be in the order of 10 -5
. In line with such predictions, we showed that vector dose-escalation can initiate murine leukemias containing combinatorial proto-oncogene activations with a frequency approaching 1 in a million treated bone marrow cells. 8 Insertional mutagenesis by retroviral vectors may induce a competitive growth advantage to murine bone marrow cells in vivo, allowing the identification of genes regulating stem cell turnover. 12 Accordingly, insertional mutagenesis by retroviral vectors allows the identification of genes that immortalize murine bone marrow cells in vitro. 13 In the present study, we took advantage of these findings to develop rapid mutagenesis assays, starting from primary murine bone marrow cells that were transduced with a known multiplicity of infection (MOI 
Materials and Methods

Retroviral vectors and vector production
The retroviral vector SF91-eGFP-wPre (LTR, Fig. 1B ) has been described previously.
14 SF91 contains the spleen focus-forming virus LTR (GenBank no. AJ224005), the post-transcriptional regulatory element (wPRE) from Woodchuck Hepatitis Virus and encodes either DsRed2 or eGFP. Retroviral self-inactivating (SinSF) vectors were recently described. 15 Briefly, the 3' U3 region is devoid of all enhancer and promoter elements, leaving the integrase attachment site intact. As an internal promoter the identical U3 region from the LTR vector was inserted to express DsRed2 or eGFP. Cell-free supernatants were generated by transient transfection of Phoenix-gp packaging cells (kindly provided by G. Nolan, Stanford) with packaging constructs coding for the gag-pol proteins (M57) and the ecotropic envelope. 16 Viral titers determined on SC1 fibroblasts were in the range of 10 6 to 10 7 infectious units/ml unconcentrated supernatant depending on the vector backbone and transgene used. All experiments were performed with thawed vector stocks of known titers (Table 1) .
Isolation of lineage negative bone marrow cells and transduction
Lineage negative (Lin -) bone marrow (BM) cells of untreated C57Bl6/J mice were transduced as previously described. 17 Briefly, Lin -cells were isolated from complete BM by magnetic sorting using lineage specific antibodies (Gr1, CD11b, CD45R/B220, CD3e, TER119; Pharmingen, Hamburg, Germany) and cryopreserved in aliquots. Prior to retroviral transduction, Lin -BM cells were prestimulated for two days (Fig. 1A) , in StemSpan HS2000 medium (CellSystems, St. Katharinen, Germany), containing 50 ng/ml mSCF, 100 ng/ml hFlt-3 ligand, 100 ng/ml hIL-11, 10 ng/ml mIL-3 (Pepro Tech, London, UK), 1% penicillin/streptomycin, 2 mM glutamine, at a density of 1-5x10 5 cells/ml. Cells were transduced on day 4 using cell numbers and a multiplicity of infection (MOI) as indicated in Results. Virus preloading was carried out on Retronectin® coated (10 µg/cm 2 ; TaKaRa, Otsu, Japan) suspension culture dishes by spinocculation for 30 min. at 4°C. Typically 1x10 5 cells
were cultured in a single well of a 24-well plate, the culture volume was 500 µl on day 4 and 1 ml on day 5 to account for increasing cell numbers. On day 5, cells were transferred to freshly prepared plates preloaded with Retronectin and retroviral vector for a second transduction. If retroviral supernatants used in side-by-side comparisons had different titers, the supernatant with the higher titer was diluted with supernatant harvest medium so that identical volumes were used for preloading.
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Replating assays
After retroviral transduction BM cells were expanded as mass cultures for two weeks in StemSpan medium containing 50 ng/ml mSCF, 100 ng/ml hFlt-3 ligand, 100 ng/ml hIL11, 10 ng/ml mIL3, 1% penicillin/streptomycin, and 2 mM glutamine. During this time cell density was adjusted to 5x10 5 cells/ml every three days and medium was gradually shifted to IMDM, 10% FCS, 1% penicillin/streptomycin, 2 mM glutamine containing the same cytokines as above. After mass culture expansion for 14 days BM cells were plated into 96-well plates at a density of 100 cells/well (in some experiments also at 10 cells/well). Two weeks later the positive wells were counted and the frequency of replating cells was calculated based on Poisson statistics using L-Calc software (Stem Cell Technologies, Vancouver, Canada). Selected clones were expanded for further characterization.
Phenotypic characterization of clonal cells
Cell surface markers of the cells from clones generated in the mutagenesis assay were characterized by FACS analysis using antibodies for cell surface markers (antibodies specific for the surface markers CD11b, Gr1, B220, CD3, Ter119, Sca1, c-Kit). Cell morphology was analyzed on cytospin slides stained with May-Grünwald/Giemsa solution.
Southern blot
Genomic DNA for Southern blot analysis was isolated from cells of expanded clones using the Blood DNA separation kit (Qiagen, Hilden, Germany). 10 µg of genomic DNA was digested with appropriate enzymes and Southern blot performed according to standard protocols. Detection was carried out with α 32 P-labelled DNA probe corresponding to the eGFP or DsRed2 cDNA , the wPRE or the flk1 intronic enhancer (Acc.No. AF061804, 500 bp probe).
PCR
LM-PCR and LAM-PCR used to obtain integration sites of LTR vectors were performed as described, 8, 18, 19 using 300-500 ng of genomic DNA. To amplify integration sites of SIN vectors, a 3' only.
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[bio]GCACTGATAATTCCGTGGTGTTGTC-3'). For exponential PCR the following primers were designed: SIN LTR2 5'-GATATCGAATTCACAACC-3'; SIN LTR3 5'-CCAATAAAGCCTCTTGCTGT-3'.
The linker and linker primers were used as described, 8, 18, 19 only.
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Results
Murine bone marrow cells acquire a growth advantage in vitro by retroviral transduction
To evaluate insertional mutagenesis by retroviral gene transfer in a relevant target cell type, we transduced murine Lin -BM cells harvested with a purity of >90% from steady-state hematopoiesis of C57Bl6 mice. Using a protocol that allows efficient and dose-controlled retroviral gene transfer in serum-free, cytokine-supplemented expansion cultures, 17 cells were treated with ecotropic retroviral particles used at a defined multiplicity of infection (MOI). Two rounds of transduction were performed on days 4 and 5 of the expansion culture, and gene transfer rates were monitored by flow cytometry.
Following retroviral gene transfer, cells were grown in cytokine-supplemented media for another 2 weeks before replating in 96-well plates. Under these conditions, mock treated cells barely survived.
In a pilot experiment (Table 1) , we transduced 10 6 Lin -cells using an MOI of 5 with replicationdefective retroviral LTR vectors (construct SF91) that expressed the DsRed2 red fluorescent protein. Using these conditions, we reproducibly recovered clones when replating cells after transduction with high vectors doses ( Table 1) .
Normalisation of expression levels and transduction efficiency of SIN and LTR vectors
To determine whether the SIN architecture reduces the risk of insertional side effects, we used gammaretroviral SIN vectors in which the internal expression cassette is under control of the same retroviral enhancer-promoter sequences that constitute the U3 region of the LTR-driven constructs. 15 Two pairs of ecotropic vectors (Fig. 1B) expressing either eGFP or DsRed2 were produced and used with identical MOIs for subsequent experiments. As described earlier, 15 the SIN vectors expressed similar levels of eGFP or DsRed2 as their LTR-counterparts, ruling out that potential differences in transforming capacity would be related to transgene expression levels. PCR analysis confirmed the only. 
LTR vector transduction induces significantly higher frequencies of replating cells than SIN vector transduction
Following transduction at high MOI (2x10), >90% of the cells were transduced, both with LTR and SIN vectors (representative data shown in Fig. 2 ). Importantly, when transducing cells with SIN vectors replating cells (step 1, Fig 1A) were obtained with reduced frequency. To account for potential differences in infectivity, we calculated the ratio of replating frequency per vector copy. Summarizing all experiments in which this value could be calculated (Table 1) , the ratio was 0.00276+/-0.00310 (n=10) for LTR vectors and 0.00023 +/-0.00029 for SIN vectors (n=6). An unpaired two-sided t-test revealed the difference to be statistically significant (P=0.037), despite inter-experimental variability (Fig. 3) . The inter-experimental variability might be explained by the variable vector copy number found in replating clones (see Fig. 5 and related text), 8 and by experimental parameters related to the culture of primary cells. Of note, the replating frequency reflects a combination of the number of independent mutants and their competitive growth in the initial bulk culture. This implies that the average frequency of replating cells does not directly reflect the number of distinct mutants. Therefore, the twelvefold numerical difference in the average frequency of replating cells/copy number between LTR and SIN vectors must not be over-interpreted. To reduce inter-experimental variability, we only.
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The minimal average vector copy number (determined on day 7) capable of triggering replating clones was 0.9 for the LTR vector, and 1.7 for the SIN vector (Table 1) . For LTR vectors, average copy numbers above 1 always gave rise to replating cells (8/8 experiments), whereas results achieved with the SIN vector were more variable (2/4 experiments). Since we normalized the frequency of replating cells for the vector copy number detected on day 7 after gene transfer, a firm conclusion can be drawn that transduction with LTR vectors significantly increases replating ability of primary murine bone marrow cells when compared with SIN vectors containing the same enhancer-promoter in an internal position. However, our data also reveal that SIN vectors are not free from transforming potential when used at high MOI in primary murine bone marrow cells.
Insertional mutagenesis is the driving force of in vitro transformation, and can also be detected following the use of SIN vectors
To examine whether insertional mutagenesis represents the driving force of the enhanced fitness detected in the replating assays, cells had to be further expanded before obtaining sufficient DNA for Southern blot, LM PCR, cellular RNA, and live cells for phenotyping studies. Importantly, only a subset (80%) of the cells surviving the replating in 96-well plates could be successfully expanded to numbers exceeding 10 6 (step 2 in Fig. 1A ). These clones showed high levels of marker gene expression, irrespective of the vector used (Fig. 2) . One of these clones (eGFP clone B, Table 2 ) showed a very robust growth and could be kept as an immortal culture. This clone also showed the most primitive cytology (Fig. 4A ) and the highest frequency of cells co-expressing c-Kit and Sca1 (Fig. 4B) . All clones showed a high contribution of cells expressing myeloid lineage antigens (Fig. 4B) . More mature cells of granulocytic morphology were not observed. Erythroid or lymphoid markers were not detected by flow cytometry (Ter119, CD3, B220; data not shown).
Southern blot data revealed that the expanding clones obtained in a given experiment contained between 3 and 10 vector insertions and were often genetically identical or shared many of their insertions (Fig. 5A) . Thirty-nine of the 51 insertion sites predicted for the set of LTR clones were sequenced from clones by LM PCR and LAM PCR, 18, 19 and compared with the RTCGD database of only.
For
-oncogenes obtained in studies with replication-competent retroviruses. 20 As shown in Table 2 , in 6 out of 8 clones examined following transduction with LTR vectors an insertion in the Evi1 protooncogene was recovered. The insertion pattern (Fig. 5B ) was reminiscent of our previous studies in which Evi1 insertions led to its upregulation associated with benign clonal dominance or leukemia induction in vivo. 7, 8, 12 Real-time RT-PCR revealed upregulation of Evi1 in all 8 clones examined after transformation by LTR vectors (Fig. 5C ). This included two clones (#1.5 and #1.8) in which no Evi1 insertion was detected, probably due to the incomplete recovery of insertion sites. Alternatively, high expression of Evi1 in these clones might represent a direct or indirect consequence of other insertional hits. These results are in agreement with a recent report, 13 suggesting that insertional mutagenesis is the driving force of clonal outgrowth in our experimental conditions. The Hoxa7 proto-oncogene, which harbored a promoter-proximal insertion in clone #6.4, was also found to be upregulated (Fig. 5C ). Of note, some clones contained more than one insertion in a potential proto-oncogene or another gene encoding proteins involved in cellular signaling pathways (Table 2 ). Many clones showed additional hits in loci that are less likely to contribute to cell expansion, probably due to the high number of insertions within one clone. Differences in copy number per clone contribute to the inter-experimental variability described above (Fig. 3) . The SIN clones also showed insertions upstream of the third exon of Evi1, matching the preferred areas of LTR vector insertions (Fig. 5B) . The third exon contains the translational start codon of a shortened Evi1 protein that lacks the so-called PR-domain. 21 In all cases, the orientation was reverse to the transcriptional orientation of Evi1, consistent with an enhancer-mediated interaction on Evi1.
Two of the three clones obtained following transduction with SIN vectors also showed a strong upregulation of Evi1 (Fig. 5C ). Only for clone SIN1.1 the level of Evi1 expression increased only slightly compared to normal cells. This clone could have been transformed by three additional hits in potential proto-oncogenes (Table 2) . Strikingly, one of the SIN clones (SIN7, Within the limitations of our data set, the frequency of sustained clonal outgrowth induced by LTR vectors at high MOI was at least 2+/-0.7 in an initial pool of 100,000 treated Lin -cells. As not all wells containing live cells after step 1 were tested for expansion and genetically analyzed, the incidence of mutagenesis obtained with LTR vectors may have been higher. To further delineate the mutation frequency, we reduced the number of initially exposed Lin -cells from 10 5 to 10 4 but could not recover any clones after transduction with the LTR vector (MOI 2x10, n=4, Table 1 ). In our assay conditions the incidence of insertional mutants obtained with LTR vectors was thus at least 2+/-0.7 in 100,000 treated cells, and lower than 1 in 10,000. While fewer clones were obtained with SIN vectors, greater numbers would have to be characterized to obtain a reliable statistics of the incidence of insertional mutants as defined by step 2 of the experiment.
We conclude that SIN vectors may hit the same genomic loci as their LTR counterparts (see Table 2 and Fig. 5B ). Nevertheless, SIN vectors significantly reduce the frequency of insertional "side effects"
when compared with LTR vectors that contain the same enhancer-promoter sequences in their U3
regions. This was revealed by the lower frequency of replating cells obtained per vector copy number detected on day 7 after gene transfer (see Table 1 and Figure 3) .
Discussion
Using a novel and convenient cell culture assay that reflects the transforming potential of insertional mutagenesis in primary murine bone marrow cells, the present study reveals that the genotoxic risk of integrating gene transfer vectors depends on vector architecture. The vectors' transforming potential could be significantly reduced, although not eliminated, with a comparatively simple maneuver:
removing the strong retroviral enhancer-promoter sequences from the LTR, and instead placing the same sequences as a monomer into an internal position of a SIN vector. SIN vectors compensate the loss of the enhancer repetition in the LTR with improved RNA processing, thus maintaining sufficient levels of transgene expression from a single vector copy. 15 The reduced number of enhancer sequences capable of long-distance interactions is expected to be a major reason for reduced insertional transformation of target cells. The SIN design also prevents direct activation of downstream alleles by residual activity of the 3'LTR promoter or read-through combined with splice-interference from the 5'LTR.
Some gene therapy strategies need relatively high levels of transgene expression, to name only bone marrow chemoprotection, 22 and antagonism of HIV infection by intracellular immunization. 23, 24 Our study reveals that insertional transformation remains a concern for these cases, given that SIN vectors with strong internal enhancers are used. Insulator sequences incorporated into the residual U3 region of the LTR may attenuate the genotoxic impact of such vectors. 25 For those applications that do not require very high levels of transgene expression (e.g., correction of metabolic disorders such as Gaucher disease), weaker internal enhancer-promoters (e.g., the cellular phosphoglycerate kinase gene promoter which is more than five-fold less active in hematopoietic cells) would be expected to further reduce the incidence and severity of insertional side effects.
Hope for reduced insertional side effects of modified gene vectors resulted from earlier findings that lentiviruses and derived vectors integrate more frequently than gammaretroviral vectors into transcribed regions of active genes, but less frequently into promoter-proximal regions. 26, 27 This is underlined by a large study of vector insertions sites recovered from long-term repopulating hematopoietic cells of non-human primates: Calmels et al. 28 were unable to recover EVI1 hits when using a lentiviral SIN vector harboring a strong internal retroviral enhancer-promoter. In contrast, they found a strong over-representation of EVI1 insertions following transduction with gammaretroviral LTR vectors, 28 very similar to murine models. 8, 12, 13 Replating assays as introduced by Du et al. 13 and only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From modified in the present report could be used to address whether and which lentiviral vectors are capable of activating this allele. Moreover, the assays could be modified to test the impact of culture conditions triggering cell cycle progression for gene transfer. Hematopoietic cells need significantly more stimulation for gammaretroviral than for lentiviral gene transfer. 29 The present assay conditions obviously introduce a bias for clones that upregulate Evi1 by insertional mutagenesis, at least when focusing on those clones that can be further expanded following the first replating. The selection for clones with Evi1 insertions was more pronounced than in an earlier study of Du et al. who used repetitive replating to establish immortal cultures of primary murine bone marrow cells following coculture with retroviral producer cells releasing a gene marking vector. 13 In contrast to this study, we avoided the pre-treatment of donor animals with 5-fluorouracil, to ensure that the assays only reflect the impact of insertional mutations, and developed culture conditions which report the selective advantage induced by insertional mutagenesis in a relatively short period of time (4-5 weeks). We also demonstrate that it is of great importance to work with cell-free vector supernatants of similar infectivity and to normalize the frequency of transformed cells for the average vector copy number in order to compare the transforming potential of different vectors.
The insertional genotoxicity assay presented here is relatively convenient, uses an appropriate readout (selective advantage under limiting dilution conditions) and target cell population (primary hematopoietic cells), and does not require leukemia induction, thus reducing the need for prolonged animal experiments. Importantly, the sensitivity of the assay is two orders of magnitude higher than that reported for cell lines in which induction of growth-factor independence was used as an indicator of insertional mutagenesis. 30 This sensitivity may result from the fact that our assay conditions determine a combined effect of mutation frequency and fitness of transformed cells. A more precise quantification should be possible on the basis of exposed cell numbers, vector dose, and a more comprehensive determination of the number of genetically distinct clones. The sensitivity of the cell culture assays and the spectrum of "productive hits" might be further increased when using a cell population that is even more prone to immortalization. Candidates are primary hematopoietic cells from genetically defined mouse strains that harbor transforming lesions. Preleukemic genes could also be engineered into the vector used for insertional immortalization. However, depending on promoter and copy number, this might lead to a substantial variability of vector-driven oncogene expression, potentially biasing the results. 31 Another interesting outlook is the adaptation of the present assays to only.
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It is important to note that Evi1 activation, which apparently was required to sustain the growth of the insertional mutants in the second step of our assay conditions, represents a clinically relevant readout:
vector integrations into the human EVI1 allele have been associated with a selective advantage of gene-modified cells in patients receiving retroviral vector-mediated gene therapy for chronic granulomatous disease.
4 EVI1 transcripts lacking the first two exons are associated with myelodysplastic syndrome and acute myeloid leukemia in humans. 21 With its large size and the unusual transcriptional regulation also involving the upstream MDS1 gene, 21 this locus may be a suitable target for all varieties of vectors that show a bias for expressed genes. Importantly, the transforming potential of Evi1 depends on the level of upregulation, 32 underlining the relevance of this allele to determine the impact of vector enhancer modifications. Using LTR vectors at a high MOI, our assays revealed an incidence of immortalized clones with Evi1 insertions between 10 -4 and 10 -5 per initially exposed Lin -cell. Considering the high MOI and the size of the vulnerable region of the Evi1 allele (>100 kb), this incidence would still be consistent with a stringent selection based on random vector insertion into this allele.
In summary, improved cell culture assays will likely play an important role in the evaluation of the functional consequences of insertional mutagenesis, and the safety validation of novel vectors designed for genetic therapies. Our study suggests that optimizations of vector design are likely to significantly reduce the toxicity of gene transfer into hematopoietic stem cells.
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For Table 1 . The cells were expanded as a mass culture for two weeks and subsequently selected on a 96-well plate (step 1).
Randomly picked clones were further expanded to numbers exceeding 10 6 for phenotyping and to harvest DNA and RNA (step 2). (B) Retroviral vectors used for transduction shown as proviruses.
LTRSF is an LTR-driven retroviral vector which has been previously described (SF91). 14 It contains a splice competent leader region including the primer binding site (θ) and the packaging signal (Ψ) and encodes either eGFP or DsRed. The U3 region containing all the enhancer/promoter elements is derived from spleen focus forming virus (SF). SINSF is a self-inactivating (SIN) retroviral vector. 15 The U3 region is almost completely deleted leaving only the integrase attachment sites intact. eGFP or DsRed are driven by the SF enhancer-promoter, identical to the cis-elements used in the LTR-driven vector. For
